科學技術-科研成果

專注给予質高價優

的生物藥

科學論文

Poster: Xu, B. et al. HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer. European Journal of Cancer, 2020, 138 (suppl. 1), S68.
EBCC 2020
Poster: Zhang, Q. et al. 287P Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study. Annals of Oncology, 2020, 31 (suppl_4), S356.
ESMO 2020
Oral: Binghe Xu, M.D., Ph.D. China-Manufactured Trastuzumab Biosimilar HLX02: Efficacy, Safety and Pharmacokinetics Comparison to Reference TZB in a Phase 3 Metastatic Breast Cancer Study. Award of excellence, Third Prize Winner.
CSCO 2020
Poster: Zhang, J. et al. Efficacy, Safety and Immunogenicity of the Biosimilar HLX03 Compared with Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis: A Randomised, Double-blind, Phase 3 Equivalence Study.
EADV 2020
Oral: Shukui Qin, M.D., Ph.D. A Bevacizumab Biosimilar, Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: A Phase 3 Study. Award of excellence, Second Prize Winner.
CSCO 2020
Poster: Qin, S. et al. 104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study. Annals of Oncology, 2020, 31 (suppl_6), S1282.
ESMO Asia 2020

知識產權

專利申請數量	PCT申請數量	國內外授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97

KU酷游(中国)